mRNA as a Therapeutics: Understanding mRNA Vaccines

Simple item page
dc.contributor.authorOǧuz F.
dc.contributor.authorAtmaca H.
dc.date.accessioned2024-07-22T08:05:07Z
dc.date.available2024-07-22T08:05:07Z
dc.date.issued2022
dc.description.abstractVaccination is one of the important approaches in the prevention and control of diseases. Although the capacity to present antigens other than the disease-specific antigen in the traditional vaccine composition provides a potential benefit by increasing its protective efficacy, many components that are not needed for the related disease are also transferred. These components can reduce vaccine activity by lowering immunity against protective antigens. The reasons such as the low effectiveness of traditional vaccines and the high cost of production and time-consuming reasons show that it is necessary to develop a new vaccine method for our world, which is struggling with epidemics almost every year. Among nucleic acids, mRNA has many advantages, such as genomic integration, induction of anti-DNA autoantibodies, and immune tolerance induced by long-term antigen expression. mRNA vaccines have become a therapeutic target for reasons such as efficacy, safety, fast and non-expensive production. The fact that mRNA triggers both humoral and cellular immunity and goes only to the cytoplasm, not to the nucleus, makes it highly efficient. The mRNA must cross the lipid bilayer barrier and entry to the cytoplasm where it is translated into protein. There are two main ways of mRNA vaccine delivery for this: ex vivo loading of mRNA into dendritic cells (DCs) and direct injection of mRNA with or without a carrier. Studies continue to understand which delivery system is therapeutically more efficient. Preclinical and clinical trials showed that mRNA vaccines trigger a long-lasting and safe immune response. © 2022 The Author (s).
dc.identifier.DOI-ID10.34172/apb.2022.028
dc.identifier.issn22285881
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12987
dc.language.isoEnglish
dc.publisherTabriz University of Medical Sciences
dc.rightsAll Open Access; Gold Open Access; Green Open Access
dc.subjectcell penetrating peptide
dc.subjectcv 9103
dc.subjectDNA antibody
dc.subjectglycoprotein gp 140
dc.subjectinfluenza vaccine
dc.subjectmessenger RNA
dc.subjectnucleic acid
dc.subjectnucleic acid vaccine
dc.subjectpolyadenylic acid
dc.subjectprotamine
dc.subjectRNA polymerase
dc.subjectRNA vaccine
dc.subjectunclassified drug
dc.subjectZika virus vaccine
dc.subjectantigen presenting cell
dc.subjectantigen specificity
dc.subjectcancer therapy
dc.subjectclinical feature
dc.subjectclinical trial (topic)
dc.subjectcomparative study
dc.subjectdendritic cell
dc.subjectdrug delivery system
dc.subjectE.G7-OVA cell line
dc.subjecthuman
dc.subjecthumoral immunity
dc.subjectimmune response
dc.subjectimmunological tolerance
dc.subjectmessenger RNA synthesis
dc.subjectnonhuman
dc.subjectphase 1 clinical trial (topic)
dc.subjectphase 2 clinical trial (topic)
dc.subjectReview
dc.subjectRNA purification
dc.subjectRNA sequence
dc.subjectRNA structure
dc.subjectvaccination
dc.subjectvaccine development
dc.titlemRNA as a Therapeutics: Understanding mRNA Vaccines
dc.typeReview

Files

Collections

Scopus Koleksiyonu